No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction

M Leusink, Toke de Keyser, NC Onland-Moret, Bert Hofman, Loes Visser, Bruno Stricker, PIW de Bakker, A Boer, Ron van Schaik, AH Zee

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Aim: Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins. Patients & methods: We analyzed the interaction between the *22 minor allele and statin use in the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, using logistic and Cox regression models. Results: In total, 771 MI cases and 6131 controls were included in the analyses. There was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the estimates from both studies were combined (interaction odds ratio: 1.27; 95% CI: 0.73-2.21; p = 0.40 for carriers of the minor T-allele). Conclusion: We found no association of the CYP3A4*22 minor allele (rs35599367) with the effectiveness of statins in reducing MI risk.
Original languageUndefined/Unknown
Pages (from-to)1471-1477
Number of pages7
JournalPharmacogenomics
Volume15
Issue number11
DOIs
Publication statusPublished - 2014

Cite this